Matches in Nanopublications for { ?s ?p ""ELLENCE is contraindicated in patients with: Severe myocardial insufficiency [see Warnings and Precautions (5.1) Recent myocardial infarction or severe arrhythmias, or previous treatment with maximum cumulative dose of anthracyclines [see Warnings and Precautions (5.1) Severe persistent drug-induced myelosuppression [see Warnings and Precautions (5.4) Severe hepatic impairment (defined as Child-Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Warnings and Precautions (5.5) Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones [see Adverse Reactions (6.1) Severe myocardial insufficiency ( 4 Recent myocardial infarction ( 4 Severe persistent drug-induced myelosuppression ( 4 Severe hepatic impairment ( 4 Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones ( 4"" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- association label ""ELLENCE is contraindicated in patients with: Severe myocardial insufficiency [see Warnings and Precautions (5.1) Recent myocardial infarction or severe arrhythmias, or previous treatment with maximum cumulative dose of anthracyclines [see Warnings and Precautions (5.1) Severe persistent drug-induced myelosuppression [see Warnings and Precautions (5.4) Severe hepatic impairment (defined as Child-Pugh Class C or serum bilirubin level greater than 5 mg/dL) [see Warnings and Precautions (5.5) Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones [see Adverse Reactions (6.1) Severe myocardial insufficiency ( 4 Recent myocardial infarction ( 4 Severe persistent drug-induced myelosuppression ( 4 Severe hepatic impairment ( 4 Severe hypersensitivity to ELLENCE, other anthracyclines, or anthracenediones ( 4"" assertion.